JP2005514366A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005514366A5 JP2005514366A5 JP2003545653A JP2003545653A JP2005514366A5 JP 2005514366 A5 JP2005514366 A5 JP 2005514366A5 JP 2003545653 A JP2003545653 A JP 2003545653A JP 2003545653 A JP2003545653 A JP 2003545653A JP 2005514366 A5 JP2005514366 A5 JP 2005514366A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutical salt
- attached
- nitrogen
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 12
- 229910052799 carbon Inorganic materials 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 10
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 5
- -1 C 1 -C 6 alkyl Chemical group 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 0 C=C(C1*2)C=C*(OC*CN)=*1C1(CCCC1)C2=O Chemical compound C=C(C1*2)C=C*(OC*CN)=*1C1(CCCC1)C2=O 0.000 description 4
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33403401P | 2001-11-20 | 2001-11-20 | |
| PCT/US2002/033624 WO2003044016A1 (en) | 2001-11-20 | 2002-11-12 | 3-SUBSTITUTED OXINDOLE β3 AGONISTS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005514366A JP2005514366A (ja) | 2005-05-19 |
| JP2005514366A5 true JP2005514366A5 (enExample) | 2006-01-05 |
Family
ID=23305290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003545653A Pending JP2005514366A (ja) | 2001-11-20 | 2002-11-12 | ３−置換オキシインドールβ３アゴニスト |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7205407B2 (enExample) |
| EP (1) | EP1448560B1 (enExample) |
| JP (1) | JP2005514366A (enExample) |
| AT (1) | ATE297925T1 (enExample) |
| AU (1) | AU2002347982A1 (enExample) |
| DE (1) | DE60204718T2 (enExample) |
| ES (1) | ES2242890T3 (enExample) |
| WO (1) | WO2003044016A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1421078B1 (en) * | 2001-08-14 | 2006-09-27 | Eli Lilly And Company | Indole derivatives as beta-3 adrenergic agonists for the treatment of type 2 diabetes |
| JP2005518357A (ja) * | 2001-11-20 | 2005-06-23 | イーライ・リリー・アンド・カンパニー | ベータ３アドレナリンアゴニスト |
| EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
| CN1953967B (zh) | 2004-04-27 | 2013-03-13 | 惠氏公司 | 孕酮受体调节剂的纯化 |
| JP2008523145A (ja) * | 2004-12-13 | 2008-07-03 | イーライ リリー アンド カンパニー | リポキシゲナーゼ阻害剤としてのスピロ誘導体 |
| AR053710A1 (es) | 2005-04-11 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos |
| MY158766A (en) * | 2005-04-11 | 2016-11-15 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
| AR056317A1 (es) * | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
| KR20070072142A (ko) * | 2005-12-30 | 2007-07-04 | 엘지.필립스 엘시디 주식회사 | 전계 발광 표시장치와 그 구동방법 |
| MX2009003874A (es) * | 2006-10-12 | 2009-04-22 | Xenon Pharmaceuticals Inc | Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos. |
| CA2665698A1 (en) * | 2006-10-12 | 2008-05-22 | Xenon Pharmaceuticals Inc. | Use of spiro-oxindole compounds as therapeutic agents |
| CL2007002953A1 (es) * | 2006-10-12 | 2008-02-01 | Xenon Pharmaceuticals Inc | Compuestos derivados de espiro-oxindol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del dolor, cancer, prurito, hiperplasia prostatica benigna, hipercolesterolemia. |
| EP2350091B1 (en) * | 2008-10-17 | 2015-06-03 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| SG10201703086VA (en) | 2008-10-17 | 2017-05-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their use as therapeutic agents |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| US20110086899A1 (en) * | 2009-10-14 | 2011-04-14 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions for oral administration |
| JP5752136B2 (ja) | 2009-10-14 | 2015-07-22 | ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | スピロ−オキシインドール化合物のための合成方法 |
| CN105726531A (zh) | 2010-02-26 | 2016-07-06 | 泽农医药公司 | 用于局部给药的螺-羟吲哚化合物的药物组合物及其作为治疗剂的用途 |
| JP5977837B2 (ja) | 2011-12-21 | 2016-08-24 | ノヴィラ・セラピューティクス・インコーポレイテッド | Ｂ型肝炎抗ウイルス剤 |
| MX373711B (es) | 2012-08-28 | 2020-05-08 | Janssen Sciences Ireland Uc | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b. |
| DK2961732T3 (en) | 2013-02-28 | 2017-07-10 | Janssen Sciences Ireland Uc | SULFAMOYLARYLAMIDS AND USE THEREOF AS MEDICINES TO TREAT HEPATITIS B |
| US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
| CN105102451B (zh) | 2013-04-03 | 2018-09-18 | 爱尔兰詹森科学公司 | N-苯基-氨甲酰衍生物及其作为药物用于治疗乙型肝炎的用途 |
| JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
| KR102244937B1 (ko) | 2013-07-25 | 2021-04-27 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 글리옥사미드 치환된 피롤아미드 유도체 및 ｂ형 간염 치료용 의약으로서의 이의 용도 |
| DK3060547T3 (en) | 2013-10-23 | 2018-01-15 | Janssen Sciences Ireland Uc | CARBOXAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATMENT OF HEPATITS B |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US9181288B2 (en) | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| EP3102225B1 (en) | 2014-02-05 | 2020-03-25 | Novira Therapeutics Inc. | Combination therapy for treatment of hbv infections |
| US11078193B2 (en) | 2014-02-06 | 2021-08-03 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| US9400280B2 (en) | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
| TW201636017A (zh) | 2015-02-05 | 2016-10-16 | 梯瓦製藥國際有限責任公司 | 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法 |
| US9884831B2 (en) | 2015-03-19 | 2018-02-06 | Novira Therapeutics, Inc. | Azocane and azonane derivatives and methods of treating hepatitis B infections |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| TW201718496A (zh) | 2015-09-29 | 2017-06-01 | 諾維拉治療公司 | B型肝炎抗病毒劑之晶型 |
| CN109640980A (zh) | 2016-04-15 | 2019-04-16 | 诺维拉治疗公司 | 包含壳体装配抑制剂的组合和方法 |
| CN111108105B (zh) | 2017-09-22 | 2023-03-31 | 朱比兰特埃皮帕德有限公司 | 作为pad抑制剂的杂环化合物 |
| KR102782563B1 (ko) | 2017-10-18 | 2025-03-14 | 주빌런트 에피파드 엘엘씨 | Pad 억제제로서의 이미다조-피리딘 화합물 |
| AU2018362046B2 (en) | 2017-11-06 | 2023-04-13 | Jubilant Prodel LLC | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
| HUE067265T2 (hu) | 2017-11-24 | 2024-10-28 | Jubilant Episcribe Llc | Heterociklusos vegyületek mint PRMT5 inhibitorok |
| EP3765453A1 (en) | 2018-03-13 | 2021-01-20 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation |
| JP2021515769A (ja) | 2018-03-14 | 2021-06-24 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | カプシド集合調節剤の投薬レジメン |
| MA55020A (fr) | 2019-02-22 | 2021-12-29 | Janssen Sciences Ireland Unlimited Co | Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b |
| AR119732A1 (es) | 2019-05-06 | 2022-01-05 | Janssen Sciences Ireland Unlimited Co | Derivados de amida útiles en el tratamiento de la infección por vhb o de enfermedades inducidas por vhb |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH624395A5 (enExample) | 1976-01-08 | 1981-07-31 | Ciba Geigy Ag | |
| CA1116598A (en) | 1977-07-13 | 1982-01-19 | William T. Comer | 3-indolyl-tertiary butylaminopropanols |
| US4234595A (en) | 1977-07-13 | 1980-11-18 | Mead Johnson & Company | 3-Indolyl-tertiary butylaminopropanols |
| US4314943A (en) | 1977-07-13 | 1982-02-09 | Mead Johnson & Company | Heterocyclic substituted aryloxy 3-indolyl-tertiary butylaminopropanols |
| JPS6010021B2 (ja) | 1979-01-31 | 1985-03-14 | 田辺製薬株式会社 | 新規ベンジルアルコ−ル誘導体及びその製法 |
| DE3423429A1 (de) | 1984-06-26 | 1986-01-02 | Beiersdorf Ag, 2000 Hamburg | Substituierte phenoxyalkylaminopropanole, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen |
| DE3426419A1 (de) | 1984-07-18 | 1986-01-23 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue oxindol-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte |
| US4728651A (en) | 1985-10-24 | 1988-03-01 | Hoechst-Roussel Pharmaceuticals Inc. | Antihypertensive thieno-isoxazoles and -pyrazoles |
| GB8528633D0 (en) | 1985-11-21 | 1985-12-24 | Beecham Group Plc | Compounds |
| US5451677A (en) | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
| NO303782B1 (no) | 1994-03-23 | 1998-08-31 | Sankyo Co | Tiazolidin- og oksazolidinderivater og farmas°ytiske preparater inneholdende slike, samt deres anvendelse til fremstilling av medikamenter |
| US5705515A (en) | 1994-04-26 | 1998-01-06 | Merck & Co., Inc. | Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity |
| IL113410A (en) | 1994-04-26 | 1999-11-30 | Merck & Co Inc | Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them |
| ZA967892B (en) | 1995-09-21 | 1998-03-18 | Lilly Co Eli | Selective β3 adrenergic agonists. |
| WO1997046556A1 (en) | 1996-06-07 | 1997-12-11 | Merck & Co., Inc. | OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
| US5808080A (en) | 1996-09-05 | 1998-09-15 | Eli Lilly And Company | Selective β3 adrenergic agonists |
| ES2171839T3 (es) | 1996-09-05 | 2002-09-16 | Lilly Co Eli | Analogos de carbazol como agonistas adrenergicos selectivos de beta3. |
| PL334833A1 (en) | 1997-01-28 | 2000-03-27 | Merck & Co Inc | Thiazolobenzenosulphonamides as beta3 agonists for treating diabetes and obesity |
| US6011048A (en) * | 1997-01-28 | 2000-01-04 | Merck & Co., Inc. | Thiazole benzenesulfonamides as β3 agonists for treatment of diabetes and obesity |
| AUPP796798A0 (en) | 1998-12-30 | 1999-01-28 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| JP2003055344A (ja) | 1999-01-29 | 2003-02-26 | Dainippon Pharmaceut Co Ltd | ３，７−ジ置換インドール誘導体及びそれを含有する医薬組成物 |
| AU6050000A (en) | 1999-07-22 | 2001-02-13 | Eli Lilly And Company | Improved method of treating type ii diabetes and obesity |
| WO2001036412A1 (en) * | 1999-11-15 | 2001-05-25 | Eli Lilly And Company | Process for the preparation of aryloxy propanolamines |
| WO2001035947A2 (en) | 1999-11-15 | 2001-05-25 | Eli Lilly And Company | Treating wasting syndromes with aryloxy propanolamines |
| US6420365B1 (en) | 2000-01-18 | 2002-07-16 | Neurogen Corporation | Imidazopyridines and related derivatives as selective modulators of bradykinin B2 receptors |
| HRP20030018A2 (en) | 2000-07-13 | 2003-04-30 | Lilly Co Eli | Beta3 adrenergic agonists |
| IL154928A0 (en) | 2000-11-10 | 2003-10-31 | Lilly Co Eli | 3-substituted oxindole beta 3 agonists |
| ATE325119T1 (de) * | 2001-08-14 | 2006-06-15 | Lilly Co Eli | 3-substituierte oxindol-beta-3-agonisten |
| EP1421078B1 (en) | 2001-08-14 | 2006-09-27 | Eli Lilly And Company | Indole derivatives as beta-3 adrenergic agonists for the treatment of type 2 diabetes |
| JP2005518357A (ja) | 2001-11-20 | 2005-06-23 | イーライ・リリー・アンド・カンパニー | ベータ３アドレナリンアゴニスト |
-
2002
- 2002-11-12 DE DE60204718T patent/DE60204718T2/de not_active Expired - Lifetime
- 2002-11-12 ES ES02784193T patent/ES2242890T3/es not_active Expired - Lifetime
- 2002-11-12 WO PCT/US2002/033624 patent/WO2003044016A1/en not_active Ceased
- 2002-11-12 JP JP2003545653A patent/JP2005514366A/ja active Pending
- 2002-11-12 US US10/495,085 patent/US7205407B2/en not_active Expired - Lifetime
- 2002-11-12 EP EP02784193A patent/EP1448560B1/en not_active Expired - Lifetime
- 2002-11-12 AT AT02784193T patent/ATE297925T1/de not_active IP Right Cessation
- 2002-11-12 AU AU2002347982A patent/AU2002347982A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005514366A5 (enExample) | ||
| JP2005518357A5 (enExample) | ||
| JP2005507872A5 (enExample) | ||
| JP2007508359A5 (enExample) | ||
| JP2007510662A5 (enExample) | ||
| JP2005510476A5 (enExample) | ||
| JP2007508362A5 (enExample) | ||
| JP2006515339A5 (enExample) | ||
| WO2005037781A3 (fr) | Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique | |
| JP2006524225A5 (enExample) | ||
| JP2007514646A5 (enExample) | ||
| JP2005523310A5 (enExample) | ||
| CY1112086T1 (el) | Συνδυασμος γλυκοπυρρολικου αλατος και ενος αγωνιστη βητα2 αδρενεργικων υποδοχεων | |
| JP2005500311A5 (enExample) | ||
| JP2011529500A5 (enExample) | ||
| JP2020517616A5 (enExample) | ||
| JP2004525150A5 (enExample) | ||
| JP2007531739A5 (enExample) | ||
| TW200643015A (en) | 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives | |
| JP2006524222A5 (enExample) | ||
| JP2004516314A5 (enExample) | ||
| JP2005517643A5 (enExample) | ||
| JP2010501478A5 (enExample) | ||
| JP2007520440A5 (enExample) | ||
| JP2005527542A5 (enExample) |